NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
HC Wainwright & Co. Maintains Buy on Checkpoint Therapeutics, Adjusts Price Target to $76 – 1-for-10 Reverse Stock Split
HC Wainwright & Co. analyst Joseph Pantginis maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy, adjusts price target to $76 - 1-for-10 reverse stock split.
